OCGN - NASDAQ

Ocugen, Inc.

OCGN·NASDAQ

$1.34

-5.1%

HealthcareBiotechnology

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$453.62M

EPS-0.2300

P/E Ratio-5.97

Earnings Date07/30/2026

43.52M

Assets

-47%

3Y-60.0%

5Y+59.0%

10Y+21.0%

55.68M

Total Liabilities

3Y+61.0%

5Y+856.0%

10Y+147.0%

-12.17M

Total Equity

-141%

3Y-116.0%

5Y-156.0%

10Y-190.0%

Ocugen, Inc. Funding & Solvency Profile

OCGN · NASDAQ

Current Assets

Cash & Cash Equivalents18.57M

Net Receivables0.00

Inventory0.00

Other Current Assets5.77M

Total Current Assets24 M

Non-Current Assets

Property, Plant & Equipment14.39M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets4.78M

Total Non-Current Assets19 M

Total Assets

43.52M

Financial Health Analysis

Current Ratio

1.06x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Working Capital

1 M

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

56% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Ocugen, Inc. Balance Sheet

OCGN • NASDAQ

Ocugen, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	18.6M	58.5M	39.5M	77.6M	95M	24M	7.4M	15.5M	7.1M	31.9M	30.9M	58.1M	8.7M	14.7M
Short-Term Investments	0.0	0.0	0.0	13.4M	0.0	0.0	0.0	0.0	900K	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	18.6M	58.5M	39.5M	90.9M	95M	24M	7.4M	15.5M	8M	31.9M	30.9M	58.1M	8.7M	14.7M
Prepaids	0.0	0.0	0.0	0.0	7.7M	1.8M	1.3M	686K	72K	95K	42K	67K	486K	23K
Other Current Assets	5.8M	3.2M	3.5M	7.6M	0.0	0.0	7M	172K	122K	78K	279K	729K	1.1M	340K
Total Current Assets	24.3M	61.7M	43M	98.5M	102.6M	25.9M	15.8M	16.4M	8.2M	32.1M	31.2M	58.9M	10.3M	15.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	14.4M	16.6M	17.3M	6.1M	1.2M	633K	222.5K	141K	2.7M	3.9M	5.2M	4.9M	2.3M	2.3M
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	200K	510K	570K	630K
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	200K	510K	570K	630K
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	151K	150.5K	137K	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	651K	1.1M	2.5M
Other Non-Current Assets	4.8M	4.2M	4.3M	4.1M	2M	865K	667.7K	736.5K	0.0	137K	137K	604K	539K	540K
Total Non-Current Assets	19.2M	20.8M	21.6M	10.1M	3.1M	1.5M	1M	1M	2.9M	4M	5.6M	6.6M	4.5M	6M
Total Assets	43.5M	82.4M	64.5M	108.6M	105.8M	27.4M	16.8M	17.4M	11M	36.1M	36.8M	65.5M	14.8M	21M
LIABILITIES
CURRENT LIABILITIES
Total Payables	6.2M	4.2M	3.2M	8.1M	2.3M	395K	1.9M	1.6M	776K	1.9M	2.3M	4.9M	2.5M	2.5M
Accounts Payable	6.2M	4.2M	3.2M	8.1M	2.3M	395K	1.9M	1.6M	776K	1.9M	2.3M	4.9M	2.5M	1M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9M
Accrued Expenses	2.1M	1.9M	1.8M	5.6M	2.6M	1.3M	2.3M	335K	1.7M	1.4M	758K	741K	864K	320K
Short Term Debt	1.3M	1.3M	0.0	0.0	0.0	234K	0.0	0.0	178K	583K	583K	405K	0.0	0.0
Capital Lease Obligations (Current)	858K	519K	574K	498K	363K	44K	172.3K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	5.9M	8.4M	10.5M	11.2M	0.0	0.0	2.3M	10M	2M	2.1M	3M	2.8M	0.0	0.0
Other Current Liabilities	6.7M	5.3M	1M	3.1M	1.7M	1.7M	-2.1M	948K	1.2M	1.2M	2.8M	2.2M	1.7M	1.1M
Total Current Liabilities	23M	21.6M	17.1M	28.5M	7M	3.6M	4.5M	2.9M	3.8M	5.2M	6.4M	8.3M	5.1M	4.4M
NON-CURRENT LIABILITIES
Long Term Debt	27.5M	27.3M	2.8M	2.3M	1.7M	1.8M	1.1M	1M	0.0	178K	761K	1.3M	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	-918K	0.0	0.0	0.0	0.0	10M	0.0	0.0	0.0	-2M	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	918K	0.0	0.0	0.0	0.0	-1M	0.0	0.0	0.0	651K	0.0	0.0
Other Non-Current Liabilities	1.6M	564K	527K	244K	0.0	0.0	9.8K	4M	18.5M	17.2M	1.5M	1M	85.3M	36.4M
Total Non-Current Liabilities	32.6M	31.2M	6.9M	6.1M	2.9M	2.2M	1.2M	15M	18.5M	17.3M	2.2M	3M	85.3M	36.4M
Capital Lease Obligations	4.4M	3.8M	4.1M	4.1M	1.6M	433K	335.5K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	55.7M	52.8M	24M	34.7M	9.9M	5.8M	5.8M	17.9M	22.3M	22.5M	8.6M	11.3M	90.4M	40.8M
SHAREHOLDERS' EQUITY
Treasury Stock	-48K	-48K	-48K	-48K	-48K	-48K	-47.9K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	1K	1K	1K	0.0	0.0	0.0	0.0	0.0	0.0	65.5M	0.0	0.0
Common Stock	3.1M	2.9M	2.6M	2.2M	2M	1.8M	527.5K	513K	159K	159K	132K	127K	6K	6K
Additional Paid-In Capital	392.8M	366.9M	324.2M	294.9M	225.5M	93.1M	62M	18.5M	196.8M	195.2M	193.6M	187.6M	35.2M	65.3M
Retained Earnings	-408.1M	-340.2M	-286.2M	-223.1M	-131.7M	-73.3M	-51.5M	-216.8M	-208.2M	-181.8M	-165.6M	-133.5M	-110.7M	-85M
Accumulated Other Comprehensive Income/Loss	61K	48K	20K	26K	0.0	0.0	0.0	-10.3M	-10.9M	-9.4M	-8M	-6.4M	-5.6M	-5.1M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	197.4M	0.0	0.0	0.0	0.0	5.6M	5.1M
Total Stockholders' Equity	-12.2M	29.6M	40.6M	74M	95.8M	21.6M	11M	-458K	-11.3M	13.6M	28.2M	54.2M	-75.6M	-19.7M
Total Equity	-12.2M	29.6M	40.6M	74M	95.8M	21.6M	11M	-458K	-11.3M	13.6M	28.2M	54.2M	-75.6M	-19.7M
SUMMARY
Total Liabilities & Equity	43.5M	82.4M	64.5M	108.6M	105.8M	27.4M	16.8M	17.4M	11M	36.1M	36.8M	65.5M	14.8M	21M
Total Investments	0.0	0.0	0.0	13.4M	0.0	0.0	151K	150.5K	1M	0.0	0.0	0.0	0.0	0.0
Total Debt	33.1M	32.5M	6.9M	6.4M	3.3M	2.5M	1.4M	238K	178K	761K	1.3M	1.8M	0.0	0.0
Net Debt	14.6M	-26M	-32.5M	-71.2M	-91.7M	-21.5M	-6M	-15.3M	-6.9M	-31.1M	-29.6M	-56.3M	-8.7M	-14.7M
Shares Outstanding	312,320,112	312,320,112	312,320,112	312,320,112	312,320,112	312,320,112	312,320,112	312,320,112	312,320,112	312,320,112	312,320,112	312,320,112	312,320,112	312,320,112

SEC Filings

OCGN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	May 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 08, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 08, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing

Showing 1 to 10 of 352 filings

Related Guides

Blog Categories

Continue your OCGN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.